Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IDXG

Interpace Biosciences (IDXG) Stock Price, News & Analysis

Interpace Biosciences logo

About Interpace Biosciences Stock (NASDAQ:IDXG)

Advanced Chart

Key Stats

Today's Range
$0.44
$0.90
50-Day Range
$4.75
$10.40
52-Week Range
$2.57
$10.42
Volume
162,869 shs
Average Volume
6,816 shs
Market Capitalization
$2.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDXG Stock News Headlines

PDI: Your Approach Needs To Change
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
PDI: Its Mega-Yield Party Was Over Years Ago
PDI: A Golden Buying Opportunity
PTY Vs. PDI: This Is The Wrong Time For PDI
See More Headlines

IDXG Stock Analysis - Frequently Asked Questions

Interpace Biosciences, Inc. (NASDAQ:IDXG) posted its quarterly earnings results on Monday, November, 4th. The business services provider reported $0.31 earnings per share for the quarter. The business services provider earned $12.30 million during the quarter. Interpace Biosciences had a negative trailing twelve-month return on equity of 8.09% and a net margin of 10.39%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol-Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX).

Company Calendar

Last Earnings
11/04/2024
Today
4/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:IDXG
Employees
152
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$800,000.00
Pretax Margin
10.93%

Debt

Sales & Book Value

Annual Sales
$40.21 million
Cash Flow
$0.33 per share
Price / Cash Flow
1.99
Book Value
($14.16) per share
Price / Book
-0.05

Miscellaneous

Free Float
4,167,000
Market Cap
$2.87 million
Optionable
Not Optionable
Beta
0.76
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:IDXG) was last updated on 4/27/2025 by MarketBeat.com Staff
From Our Partners